Recent progress in studying curcumin and its nano-preparations for cancer therapy

Current Pharmaceutical Design

Volumn 19, Issue 11, 2013, Pages 1974-1993

  Liu, Jieying ^a   Chen, Siyuan ^c   Lv, Li ^a   Song, Lei ^a   Guo, Shengrong ^a   Huang, Shengtang ^a,b  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

^b HUBEI UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^c SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Cancer therapy; Curcumin; Nano preparations

Indexed keywords

CAMPTOTHECIN; CELECOXIB; CISPLATIN; CURCUMIN; CYCLIN DEPENDENT KINASE; CYCLINE; CYCLODEXTRIN; DOXORUBICIN; ETOPOSIDE; FIBROBLAST GROWTH FACTOR 2; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; LIPOSOME; MATRIX METALLOPROTEINASE; MICROSOMAL AMINOPEPTIDASE; MITOGEN ACTIVATED PROTEIN KINASE; NANODISK; NANOFIBER; NANOPARTICLE; OXALIPLATIN; PACLITAXEL; RADIOSENSITIZING AGENT; SOLID LIPID NANOPARTICLE; TELOMERASE; TRICHOSTATIN A; TURMERIC; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN; VINCRISTINE;

ALZHEIMER DISEASE; ANTIANGIOGENIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; AUTOPHAGY; CANCER RESISTANCE; CANCER THERAPY; CARDIOVASCULAR DISEASE; CELL DIFFERENTIATION; CHINA; CYTOTOXICITY; DIABETES MELLITUS; DRUG ABSORPTION; DRUG CONJUGATION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG EXCRETION; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DRUG SENSITIZATION; DRUG SOLUBILITY; DRUG TARGETING; DRUG TRANSFORMATION; ENTERITIS; GENOTOXICITY; HEART MUSCLE INJURY; HYDROPHOBICITY; INDIA; LUNG FIBROSIS; MALIGNANT TRANSFORMATION; METASTASIS INHIBITION; MICELLE; MITOSIS; NANOEMULSION; NEOPLASM; NEPHROTOXICITY; PARTICLE SIZE; PRIORITY JOURNAL; RADIATION PROTECTION; REVIEW; RHEUMATOID ARTHRITIS; SKIN TOXICITY; WOUND HEALING; ZETA POTENTIAL;

EID: 84875402025     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612811319110003     Document Type: Review

References (228)

1. Anand P, Thomas SG, Kunnumakkara AB, et al. Biological activities of curcumin and its analogues (Congeners) made by man and Mother Nature. Biochem Pharmacol 2008; 76: 1590-611.
2. Kunnumakkara AB, Anand P, Aggarwal BB. Curcumin inhibits proliferation, invasion, angiogenesis and metastasis of different cancers through interaction with multiple cell signaling proteins. Cancer Lett 2008; 269: 199-225.
3. Goel A, Kunnumakkara AB, Aggarwal BB. Curcumin as Curecumin: from kitchen to clinic. Biochem Pharmacol 2008; 75: 787-809.
4. Li X. Study on allelopathy of C. wenyujin and Curcuma phaeocaulis Valetion. Fujian Agriculture and Forestry University, Graduate Thesis 2010.
5. Aggarwal BB, Y.J. S, Shishodia S. The molecular targets and therapeutic uses of curcumin in health and disease. Adv Exp Med Biol 2007; 595.
6. Priyadarsini KI. Photophysics, photochemistry and photobiology of curcumin: Studies from organic solutions, bio-mimetics and living cells. Journal of Photochemistry and Photobiology C: Photochemistry Reviews 2009; 10: 81-95.
7. Wang YJ, Pan MH, Cheng AL, et al. Stability of curcumin in buffer solutions and characterization of its degradation products. J Pharm Biomed Anal 1997; 15: 1867-76.
8. Lin JK, Pan MH, Lin-Shiau SY. Recent studies on the biofunctions and biotransformations of curcumin. Biofactors 2000; 13: 153-158.
9. Jiao Y, Wilkinson JT, Christine Pietsch E, et al. Iron chelation in the biological activity of curcumin. Free Radic Biol Med 2006; 40: 1152-60.
10. Feng SG, Qin GY, Liu HX, et al. Isolation and identification of degradation products of curcumin and study of stability of curcumin. Journal of Shenyang Pharmaceutical University 2009; 26: 361-365, 396.
11. Wahlstrom B, Blennow G. A study on the fate of curcumin in the rat. Acta Pharmacol Toxicol (Copenh) 1978; 43: 86-92.
12. Ravindranath V, Chandrasekhara N. Absorption and tissue distribution of curcumin in rats. Toxicology 1980; 16: 259-65.
13. Pan MH, Huang TM, Lin JK. Biotransformation of curcumin through reduction and glucuronidation in mice. Drug Metab Dispos 1999; 27: 486-94.
14. Maiti K, Mukherjee K, Gantait A, Saha BP, Mukherjee PK. Curcumin-phospholipid complex: Preparation, therapeutic evaluation and pharmacokinetic study in rats. Int J Pharm 2007; 330: 155-63.
15. Vareed SK, Kakarala M, Ruffin MT, et al. Pharmacokinetics of curcumin conjugate metabolites in healthy human subjects. Cancer Epidemiol Biomarkers Prev 2008; 17: 1411-7.
16. Hong D, Zeng X, Xu W, et al. Altered profiles of gene expression in curcumin-treated rats with experimentally induced myocardial infarction. Pharmacological Research 2010; 61: 142-148.
17. Morimoto T, Sunagawa Y, Fujita M, Hasegawa K. Novel heart failure therapy targeting transcriptional pathway in cardiomyocytes by a natural compound, curcumin. Circulation Journal 2010; 74: 1060-1066.
18. Ukil A, Maity S, Karmakar S, et al. Curcumin, the major component of food flavour turmeric, reduces mucosal injury in trinitrobenzene sulphonic acid-induced colitis. Br J Pharmacol 2003; 139: 209-18.
19. Panchatcharam M, Miriyala S, Gayathri VS, Suguna L. Curcumin improves wound healing by modulating collagen and decreasing reactive oxygen species. Mol Cell Biochem 2006; 290: 87-96.
20. Bhagavathula N, Warner RL, DaSilva M, et al. A combination of curcumin and ginger extract improves abrasion wound healing in corticosteroid-impaired hairless rat skin. Wound Repair Regen 2009; 17: 360-6.
21. Lim GP, Chu T, Yang F, et al. The curry spice curcumin reduces oxidative damage and amyloid pathology in an Alzheimer transgenic mouse. J Neurosci 2001; 21: 8370-7.
22. Mathew A, Fukuda T, Nagaoka Y, et al. Curcumin loaded-PLGA nanoparticles conjugated with Tet-1 peptide for potential use in Alzheimer's disease. PLoS One 2012; 7.
23. Deodhar SD, Sethi R, Srimal RC. Preliminary study on antirheumatic activity of curcumin (diferuloyl methane). Indian J Med Res 1980; 71: 632-4.
24. Chandran B, Goel A. A Randomized, Pilot Study to Assess the Efficacy and Safety of Curcumin in Patients with Active Rheumatoid Arthritis. Phytotherapy Research 2012.
25. Aggarwal BB, Shishodia S, Takada Y, et al. Curcumin suppresses the paclitaxel-induced nuclear factor-kappaB pathway in breast cancer cells and inhibits lung metastasis of human breast cancer in nude mice. Clin Cancer Res 2005; 11: 7490-8.
26. Soetikno V, Watanabe K, Sari FR, et al. Curcumin attenuates diabetic nephropathy by inhibiting PKC-α and PKC-α1 activity in streptozotocin-induced type I diabetic rats. Molecular Nutrition and Food Research 2011; 55: 1655-1665.
27. Ali BH, Marrif H, Noureldayem SA, Bakheit AO, Blunden G. Some biological properties of curcumin: A review. Natural Product Communications 2006; 1: 509-521.
28. Unnikrishnan MK, Rao MN. Curcumin inhibits nitrogen dioxide induced oxidation of hemoglobin. Mol Cell Biochem 1995; 146: 35-7.
29. Khalil OAK, de Faria Oliveira OMM, Vellosa JCR, et al. Curcumin antifungal and antioxidant activities are increased in the presence of ascorbic acid. Food Chemistry 2012; 133: 1001-1005.
30. Holt PR, Katz S, Kirshoff R. Curcumin therapy in inflammatory bowel disease: a pilot study. Dig Dis Sci 2005; 50: 2191-3.
31. Bereswill S, Muñoz M, Fischer A, et al. Anti-inflammatory effects of Resveratrol, Curcumin and Simvastatin in acute small intestinal inflammation. PLoS One 2010; 5.
32. Kunwar A, Jayakumar S, Srivastava AK, Priyadarsini KI. Dimethoxycurcumin-induced cell death in human breast carcinoma MCF7 cells: evidence for pro-oxidant activity, mitochondrial dysfunction, and apoptosis. Archives of Toxicology 2011: 1-12.
33. Kunwar A, Barik A, Sandur SK, Priyadarsini IK. Differential antioxidant/pro-oxidant activity of dimethoxycurcumin, a synthetic analogue of curcumin. Free Radical Research 2011; 45: 959-965.
34. Cheng AL, Hsu CH, Lin JK, et al. Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res 2001; 21: 2895-900.
35. Sharma RA, Euden SA, Platton SL, et al. Phase I clinical trial of oral curcumin: biomarkers of systemic activity and compliance. Clin Cancer Res 2004; 10: 6847-54.
36. Woo JH, Kim YH, Choi YJ, et al. Molecular mechanisms of curcumin-induced cytotoxicity: Induction of apoptosis through generation of reactive oxygen species, down-regulation of Bcl-XL and IAP, the release of cytochrome c and inhibition of Akt. Carcinogenesis 2003; 24: 1199-1208.
37. Singh M, Pandey A, Karikari CA, Singh G, Rakheja D. Cell cycle inhibition and apoptosis induced by Curcumin in Ewing sarcoma cell line SK-NEP-1. Medical Oncology 2010; 27: 1096-1101.
38. Aggarwal BB. Nuclear factor-κB: The enemy within. Cancer Cell 2004; 6: 203-208.
39. Cao J, Liu Y, Jia L, et al. Curcumin induces apoptosis through mitochondrial hyperpolarization and mtDNA damage in human hepatoma G2 cells. Free Radical Biology and Medicine 2007; 43: 968-975.
40. Tian B, Wang Z, Zhao Y, et al. Effects of curcumin on bladder cancer cells and development of urothelial tumors in a rat bladder carcinogenesis model. Cancer Lett 2008; 264: 299-308.
41. Yang CL, Ma YG, Xue YX, et al. Curcumin induces small cell lung cancer NCI-H446 cell apoptosis via the reactive oxygen species-mediated mitochondrial pathway and not the cell death receptor pathway. DNA Cell Biol 2012; 31: 139-50.
42. Friedman L, Lin L, Ball S, et al. Curcumin analogues exhibit enhanced growth suppressive activity in human pancreatic cancer cells. Anti-Cancer Drugs 2009; 20: 444-449.
43. Sandur SK, Pandey MK, Sung B, et al. Curcumin, demethoxycurcumin, bisdemethoxycurcumin, tetrahydrocurcumin and turmerones differentially regulate anti-inflammatory and antiproliferative responses through a ROS-independent mechanism. Carcinogenesis 2007; 28: 1765-1773.
44. Karunagaran D, Rashmi R, Santhosh Kumar TR. Induction of apoptosis by curcumin and its implications for cancer therapy. Current Cancer Drug Targets 2005; 5: 117-129.
45. Jee SH, Shen SC, Tseng CR, Chiu HC, Kuo ML. Curcumin induces a p53-dependent apoptosis in human basal cell carcinoma cells. Journal of Investigative Dermatology 1998; 111: 656-661.
46. Watson JL, Hill R, Yaffe PB, et al. Curcumin causes superoxide anion production and p53-independent apoptosis in human colon cancer cells. Cancer Lett 2010; 297: 1-8.
47. Collett GP, Campbell FC. Curcumin induces c-jun N-terminal kinase-dependent apoptosis in HCT116 human colon cancer cells. Carcinogenesis 2004; 25: 2183-2189.
48. Gururaj AE, Belakavadi M, Venkatesh DA, Marmé D, Salimath BP. Molecular mechanisms of anti-angiogenic effect of curcumin. Biochem Biophys Res Commun 2002; 297: 934-942.
49. Shih SC, Claffey KP. Role of AP-1 and HIF-1 transcription factors in TGF-β activation of VEGF expression. Growth Factors 2001; 19: 19-34.
50. Arbiser JL, Klauber N, Rohan R, et al. Curcumin is an in vivo inhibitor of angiogenesis. Molecular Medicine 1998; 4: 376-383.
51. Shao ZM, Shen ZZ, Liu CH, et al. Curcumin exerts multiple suppressive effects on human breast carcinoma cells. International Journal of Cancer 2002; 98: 234-240.
52. Gupta B, Ghosh B. Curcuma longa inhibits TNF-α induced expression of adhesion molecules on human umbilical vein endothelial cells. International Journal of Immunopharmacology 1999; 21: 745-757.
53. Shim JS, Kim JH, Cho HY, et al. Irreversible inhibition of CD13/aminopeptidase N by the antiangiogenic agent curcumin. Chemistry and Biology 2003; 10: 695-704.
54. Li L, Braiteh FS, Kurzrock R. Liposome-encapsulated curcumin: In vitro and in vivo effects on proliferation, apoptosis, signaling, and angiogenesis. Cancer 2005; 104: 1322-1331.
55. Aggarwal BB, Banerjee S, Bharadwaj U, et al. Curcumin induces the degradation of cyclin E expression through ubiquitin-dependent pathway and up-regulates cyclin-dependent kinase inhibitors p21 and p27 in multiple human tumor cell lines. Biochem Pharmacol 2007; 73: 1024-1032.
56. Jaiswal AS, Marlow BP, Gupta N, Narayan S. β-catenin-mediated transactivation and cell-cell adhesion pathways are important in curcumin (diferuylmethane)-induced growth arrest and apoptosis in colon cancer cells. Oncogene 2002; 21: 8414-8427.
57. Liu Q, Loo WT, Sze SC, Tong Y. Curcumin inhibits cell proliferation of MDA-MB-231 and BT-483 breast cancer cells mediated by down-regulation of NFκB, cyclinD and MMP-1 transcription. Phytomedicine 2009; 16: 916-22.
58. Chaudhary LR, Hruska KA. Inhibition of cell survival signal protein kinase B/Akt by curcumin in human prostate cancer cells. Journal of Cellular Biochemistry 2003; 89: 1-5.
59. Yan C, Jamaluddin MS, Aggarwal B, Myers J, Boyd DD. Gene expression profiling identifies activating transcription factor 3 as a novel contributor to the proapoptotic effect of curcumin. Mol Cancer Ther 2005; 4: 233-241.
60. Deryugina EI, Quigley JP. Matrix metalloproteinases and tumor metastasis. Cancer and Metastasis Reviews 2006; 25: 9-34.
61. Lev-Ari S, Starr A, Vexler A, et al. Inhibition of pancreatic and lung adenocarcinoma cell survival by curcumin is associated with increased apoptosis, down-regulation of COX-2 and EGFR and inhibition of Erk1/2 activity. Anticancer Research 2006; 26: 4423-4430.
62. Somers-Edgar TJ, Taurin S, Larsen L, et al. Mechanisms for the activity of heterocyclic cyclohexanone curcumin derivatives in estrogen receptor negative human breast cancer cell lines. Investigational New Drugs 2011; 29: 87-97.
63. Swarnakar S, Ganguly K, Kundu P, et al. Curcumin regulates expression and activity of matrix metalloproteinases 9 and 2 during prevention and healing of indomethacin-induced gastric ulcer. Journal of Biological Chemistry 2005; 280: 9409-9415.
64. Banerji A, Chakrabarti J, Mitra A, Chatterjee A. Effect of curcumin on gelatinase a (MMP-2) activity in B16F10 melanoma cells. Cancer Lett 2004; 211: 235-242.
65. Narayan S. Curcumin, a multi-functional chemopreventive agent, blocks growth of colon cancer cells by targeting β-cateninmediated transactivation and cell-cell adhesion pathways. Journal of Molecular Histology 2004; 35: 301-307.
66. Seol DW, Chen Q, Zarnegar R. Transcriptional activation of the Hepatocyte Growth Factor receptor (c-met) gene by its ligand (Hepatocyte Growth Factor) is mediated through AP-1. Oncogene 2000; 19: 1132-1137.
67. Gupta KK, Bharne SS, Rathinasamy K, Naik NR, Panda D. Dietary antioxidant curcumin inhibits microtubule assembly through tubulin binding. FEBS Journal 2006; 273: 5320-5332.
68. Aoki H, Takada Y, Kondo S, et al. Evidence that curcumin suppresses the growth of malignant gliomas in vitro and in vivo through induction of autophagy: Role of akt and extracellular signal-regulated kinase signaling pathways. Mol Pharmacol 2007; 72: 29-39.
69. O'Sullivan-Coyne G, O'Sullivan GC, O'Donovan TR, Piwocka K, McKenna SL. Curcumin induces apoptosis-independent death in oesophageal cancer cells. Br J Cancer 2009; 101: 1585-1595.
70. Yu S, Shen G, Tin OK, Kim JH, Kong ANT. Curcumin inhibits Akt/mammalian target of rapamycin signaling through protein phosphatase-dependent mechanism. Mol Cancer Ther 2008; 7: 2609-2620.
71. Zhang HN, Yu CX, Zhang PJ, et al. Curcumin downregulates homeobox gene NKX3.1 in prostate cancer cell LNCaP. Acta Pharmacologica Sinica 2007; 28: 423-430.
72. Kim S, Domon-Dell C, Wang Q, et al. PTEN and TNF-α regulation of the intestinal-specific Cdx-2 homeobox gene through a PI3K, PKB/Akt, and NF-βB-dependent pathway. Gastroenterology 2002; 123: 1163-1178.
73. Hidaka H, Ishiko T, Furuhashi T, et al. Curcumin inhibits interleukin 8 production and enhances interleukin 8 receptor expression on the cell surface: Impact on human pancreatic carcinoma cell growth by autocrine regulation. Cancer 2002; 95: 1206-1214.
74. Menon LG, Kuttan R, Kuttan G. Inhibition of lung metastasis in mice induced by B16F10 melanoma cells by polyphenolic compounds. Cancer Lett 1995; 95: 221-225.
75. Ray S, Chattopadhyay N, Mitra A, Siddiqi M, Chatterjee A. Curcumin exhibits antimetastatic properties by modulating integrin receptors, collagenase activity, and expression of Nm23 and Ecadherin. Journal of Environmental Pathology, Toxicology and Oncology 2003; 22: 49-58.
76. Hong JH, Ahn KS, Bae E, Jeon SS, Choi HY. The effects of curcumin on the invasiveness of prostate cancer in vitro and in vivo. Prostate Cancer and Prostatic Diseases 2006; 9: 147-152.
77. Dorai T, Dutcher JP, Dempster DW, Wiernik PH. Therapeutic potential of curcumin in prostate cancer-IV: Interference with the osteomimetic properties of hormone refractory C4-2B prostate cancer cells. Prostate 2004; 60: 1-17.
78. Philip S, Bulbule A, Kundu GC. Matrix metalloproteinase-2: Mechanism and regulation of NF-κB-mediated activation and its role in cell motility and ECM-invasion. Glycoconjugate Journal 2004; 21: 429-441.
79. Mukherjee S, Ghosh U, Bhattacharyya NP, et al. Curcumininduced apoptosis in human leukemia cell HL-60 is associated with inhibition of telomerase activity. Molecular and Cellular Biochemistry 2007; 297: 31-39.
80. Kim NW, Piatyszek MA, Prowse KR, et al. Specific association of human telomerase activity with immortal cells and cancer. Science 1994; 266: 2011-2015.
81. Chakraborty S, Ghosh U, Bhattacharyya NP, Bhattacharya RK, Roy M. Inhibition of telomerase activity and induction of apoptosis by curcumin in K-562 cells. Mutation Research-Fundamental and Molecular Mechanisms of Mutagenesis 2006; 596: 81-90.
82. Ramachandran C, Fonseca HB, Jhabvala P, Escalon EA, Melnick SJ. Curcumin inhibits telomerase activity through human telomerase reverse transcritpase in MCF-7 breast cancer cell line. Cancer Lett 2002; 184: 1-6.
83. Kapoor N, Sharma AK, Dwivedi V, et al. Telomerase targeted anticancer bioactive prodrug by antisense-based approach. Cancer Lett 2007; 248: 245-250.
84. Li Y, Revalde JL, Reid G, Paxton JW. Modulatory effects of curcumin on multi-drug resistance-associated protein 5 in pancreatic cancer cells. Cancer Chemother Pharmacol 2011; 68: 603-10.
85. Hour TC, Chen J, Huang CY, et al. Curcumin enhances cytotoxicity of chemotherapeutic agents in prostate cancer cells by inducing p21WAF1/CIP1 and C/EBPβ expressions and suppressing NF-κB activation. Prostate 2002; 51: 211-218.
86. Patel BB, Sengupta R, Qazi S, et al. Curcumin enhances the effects of 5-fluorouracil and oxaliplatin in mediating growth inhibition of colon cancer cells by modulating EGFR and IGF-1R. International Journal of Cancer 2008; 122: 267-273.
87. Koo JY, Kim HJ, Jung KO, Park KY. Curcumin inhibits the growth of AGS human gastric carcinoma cells in vitro and shows synergism with 5-fluorouracil. Journal of Medicinal Food 2004; 7: 117-121.
88. Jiang LP, Du BY, Zhong LF. Combined effect of curcumin and 5-FU on apoptosis and COX-2 expression in human colon carcinoma cell line HT-29. Journal of China Pharmaceutical University 2006; 37: 555-558.
89. Lev-Ari S, Zinger H, Kazanov D, et al. Curcumin synergistically potentiates the growth inhibitory and pro-apoptotic effects of celecoxib in pancreatic adenocarcinoma cells. Biomedicine and Pharmacotherapy 2005; 59: S276-S280.
90. Lev-Ari S, Strier L, Kazanov D, et al. Celecoxib and curcumin synergistically inhibit the growth of colorectal cancer cells. Clinical Cancer Research 2005; 11: 6738-6744.
91. Shpitz B, Giladi N, Sagiv E, et al. Celecoxib and curcumin additively inhibit the growth of colorectal cancer in a rat model. Digestion 2006; 74: 140-144.
92. Lev-Ari S, Vexler A, Starr A, et al. Curcumin augments gemcitabine cytotoxic effect on pancreatic adenocarcinoma cell lines. Cancer Investigation 2007; 25: 411-418.
93. Kunnumakkara AB, Guha S, Krishnan S, et al. Curcumin potentiates antitumor activity of gemcitabine in an orthotopic model of pancreatic cancer through suppression of proliferation, angiogenesis, and inhibition of nuclear factor-κB-regulated gene products. Cancer Res 2007; 67: 3853-3861.
94. Notarbartolo M, Poma P, Perri D, et al. Antitumor effects of curcumin, alone or in combination with cisplatin or doxorubicin, on human hepatic cancer cells. Analysis of their possible relationship to changes in NF-κB activation levels and in IAP gene expression. Cancer Lett 2005; 224: 53-65.
95. Holcomb B, Yip-Schneider MT, Matos JM, et al. Pancreatic cancer cell genetics and signaling response to treatment correlate with efficacy of gemcitabine-based molecular targeting strategies. Journal of Gastrointestinal Surgery: Official Journal of the Society for Surgery of the Alimentary Tract 2008; 12: 288-296.
96. Li M, Zhang Z, Hill DL, Wang H, Zhang R. Curcumin, a dietary component, has anticancer, chemosensitization, and radiosensitization effects by down-regulating the MDM2 oncogene through the PI3K/mTOR/ETS2 pathway. Cancer Res 2007; 67: 1988-1996.
97. Kamat AM, Sethi G, Aggarwal BB. Curcumin potentiates the apoptotic effects of chemotherapeutic agents and cytokines through down-regulation of nuclear factor-κB and nuclear factor-κBregulated gene products in IFN-α-sensitive and IFN-α-resistant human bladder cancer cells. Mol Cancer Ther 2007; 6: 1022-1030.
98. Venkatraman M, Anto RJ, Nair A, Varghese M, Karunagaran D. Biological and chemical inhibitors of NF-κB sensitize SiHa cells to cisplatin-induced apoptosis. Mol Carcinog 2005; 44: 51-59.
99. Bava SV, Puliappadamba VT, Deepti A, et al. Sensitization of taxol-induced apoptosis by curcumin involves down-regulation of nuclear factor-κB and the serine/threonine kinase Akt and is independent of tubulin polymerization. Journal of Biological Chemistry 2005; 280: 6301-6308.
100. Chirnomas D, Taniguchi T, De La Vega M, et al. Chemosensitization to cisplatin by inhibitors of the Fanconi anemia/BRCA pathway. Mol Cancer Ther 2006; 5: 952-961.
101. Chan MM, Fong D, Soprano KJ, Holmes WF, Heverling H. Inhibition of growth and sensitization to cisplatin-mediated killing of ovarian cancer cells by polyphenolic chemopreventive agents. Journal of Cellular Physiology 2003; 194: 63-70.
102. Misra R, Sahoo SK. Coformulation of Doxorubicin and Curcumin in Poly(d,l-lactide-co-glycolide) Nanoparticles Suppresses the Development of Multidrug Resistance in K562 Cells. molecular pharmaceutics 2011; 8: 852-866.
103. Odot J, Albert P, Carlier A, et al. In vitro and in vivo anti-tumoral effect of curcumin against melanoma cells. International Journal of Cancer 2004; 111: 381-387.
104. Aggarwal BB, Shishodia S, Takada Y, et al. Curcumin suppresses the paclitaxel-induced nuclear factor-κB pathway in breast cancer cells and inhibits lung metastasis of human breast cancer in nude mice. Clinical Cancer Research 2005; 11: 7490-7498.
105. Srinivas Ganta MA. Coadministration of Paclitaxel and Curcumin in Nanoemulsion Formulations to Overcome Multidrug Resistance in Tumor Cells. Molecular Pharmaceutics 2009; 6: 928-939.
106. Ganta S, Devalapally H, Amiji M. Curcumin enhances oral bioavailability and anti-tumor therapeutic efficacy of paclitaxel upon administration in nanoemulsion formulation. J Pharm Sci 2010; 99: 4630-41.
107. Ganga S. Multifunctional Nanoemulsion System for Combination Paclitaxel and Curcumin Delivery in human glioblastoma cells. Pharmaceutical Science Master's Theses 2008.
108. Li L, Ahmed B, Mehta K, Kurzrock R. Liposomal curcumin with and without oxaliplatin: effects on cell growth, apoptosis, and angiogenesis in colorectal cancer. Mol Cancer Ther 2007; 6: 1276-82.
109. Howells LM, Sale S, Sriramareddy SN, et al. Curcumin ameliorates oxaliplatin-induced chemoresistance in HCT116 colorectal cancer cells in vitro and in vivo. Int J Cancer 2011; 129: 476-86.
110. Limtrakul P, Anuchapreeda S, Buddhasukh D. Modulation of human multidrug-resistance MDR-1 gene by natural curcuminoids. BMC Cancer 2004; 4.
111. Somasundaram S, Edmund NA, Moore DT, et al. Dietary curcumin inhibits chemotherapy-induced apoptosis in models of human breast cancer. Cancer Res 2002; 62: 3868-3875.
112. Yan G, Graham K, Lanza-Jacoby S. Curcumin enhances the anticancer effects of trichostatin a in breast cancer cells. Mol Carcinog 2012.
113. Sen S, Sharma H, Singh N. Curcumin enhances Vinorelbine mediated apoptosis in NSCLC cells by the mitochondrial pathway. Biochem Biophys Res Commun 2005; 331: 1245-1252.
114. Prasanna R, Chinnakonda Chandramoorthy H, Ramaiyapillai P, Sakthisekaran D. In vitro evaluation of anticancer effect of Cassia auriculata leaf extract and curcumin through induction of apoptosis in human breast and larynx cancer cell lines. Biomedicine & Preventive Nutrition 2011; 1: 153-160.
115. Andjelkovic T, Pesic M, Bankovic J, et al. Synergistic effects of the purine analog sulfinosine and curcumin on the multidrug resistant human non-small cell lung carcinoma cell line (NCIH460/ R). Cancer Biology and Therapy 2008; 7: 1024-1032.
116. Sung B, Kunnumakkara AB, Sethi G, et al. Curcumin circumvents chemoresistance in vitro and potentiates the effect of thalidomide and bortezomib against human multiple myeloma in nude mice model (Molecular Cancer Therapeutics (2009) 8, (959-970)). Mol Cancer Ther 2009; 8: 1398.
117. Indap MA, Barkume MS. Efficacies of plant phenolic compounds on sodium butyrate induced anti-tumour activity. Indian Journal of Experimental Biology 2003; 41: 861-864.
118. Tang XQ, Bi H, Feng JQ, Cao JG. Effect of curcumin on multidrug resistance in resistant human gastric carcinoma cell line SGC7901/VCR. Acta Pharmacologica Sinica 2005; 26: 1009-1016.
119. Everett PC, Meyers JA, Makkinje A, Rabbi M, Lerner A. Preclinical assessment of curcumin as a potential therapy for BCLL. American Journal of Hematology 2007; 82: 23-30.
120. Ko JC, Tsai MS, Weng SH, et al. Curcumin enhances the mitomycin C-induced cytotoxicity via downregulation of MKK1/2-ERK1/2-mediated Rad51 expression in non-small cell lung cancer cells. Toxicol Appl Pharmacol 2011; 255: 327-38.
121. Chendil D, Ranga RS, Meigooni D, Sathishkumar S, Ahmed MM. Curcumin confers radiosensitizing effect in prostate cancer cell line PC-3. Oncogene 2004; 23: 1599-1607.
122. Dhandapani KM, Mahesh VB, Brann DW. Curcumin suppresses growth and chemoresistance of human glioblastoma cells via AP-1 and NFκB transcription factors. Journal of Neurochemistry 2007; 102: 522-538.
123. Kunnumakkara AB, Diagaradjane P, Guha S, et al. Curcumin sensitizes human colorectal cancer xenografts in nude mice to γ-radiation by targeting nuclear factor-κB-regulated gene products. Clinical Cancer Research 2008; 14: 2128-2136.
124. Aravindan N, Madhusoodhanan R, Ahmad S, Johnson D, Herman TS. Curcumin inhibits NFκB mediated radioprotection and modulate apoptosis related genes in human neuroblastoma cells. Cancer Biology and Therapy 2008; 7: 569-576.
125. Khafif A, Lev-Ari S, Vexler A, et al. Curcumin: a potential radioenhancer in head and neck cancer. Laryngoscope 2009; 119: 2019-26.
126. Javvadi P, Segan AT, Tuttle SW, Koumenis C. The chemopreventive agent curcumin is a potent radiosensitizer of human cervical tumor cells via increased reactive oxygen species production and overactivation of the mitogen-activated protein kinase pathway. Mol Pharmacol 2008; 73: 1491-1501.
127. Chan WH, Wu CC, Yu JS. Curcumin inhibits UV irradiationinduced oxidative stress and apoptotic biochemical changes in human epidermoid carcinoma A431 cells. Journal of Cellular Biochemistry 2003; 90: 327-338.
128. Chan WH, Wu HJ. Anti-apoptotic effects of curcumin on photosensitized human epidermal carcinoma A431 cells. Journal of Cellular Biochemistry 2004; 92: 200-212.
129. Araújo MCP, Da Luz Dias F, Takahashi CS. Potentiation by turmeric and curcumin of γ-radiation-induced chromosome aberrations in Chinese hamster ovary cells. Teratogenesis Carcinogenesis and Mutagenesis 1999; 19: 9-18.
130. Park K, Lee JH. Photosensitizer effect of curcumin on UVBirradiated HaCaT cells through activation of caspase pathways. Oncology reports 2007; 17: 537-540.
131. Kuhad A, Pilkhwal S, Sharma S, Tirkey N, Chopra K. Effect of curcumin on inflammation and oxidative stress in cisplatin-induced experimental nephrotoxicity. J Agric Food Chem 2007; 55: 10150-10155.
132. Venkatesan N, Punithavathi D, Arumugam V. Curcumin prevents adriamycin nephrotoxicity in rats. British Journal of Pharmacology 2000; 129: 231-234.
133. van't Land B, Blijlevens NMA, Marteijn J, et al. Role of curcumin and the inhibition of NF-κB in the onset of chemotherapy-induced mucosal barrier injury. Leukemia 2004; 18: 276-284.
134. Rezvani M, Ross GA. Modification of radiation-induced acute oral mucositis in the rat. International Journal of Radiation Biology 2004; 80: 177-182.
135. Venkatesan N. Curcumin attenuation of acute adriamycin myocardial toxicity in rats. British Journal of Pharmacology 1998; 124: 425-427.
136. Punithavathi D, Venkatesan N, Babu M. Curcumin inhibition of bleomycin-induced pulmonary fibrosis in rats. British Journal of Pharmacology 2000; 131: 169-172.
137. Thresiamma KC, George J, Kuttan R. Protective effect of curcumin, ellagic acid and bixin on radiation induced toxicity. Indian Journal of Experimental Biology 1996; 34: 845-847.
138. Parshad R, Sanford KK, Price FM, et al. Protective action of plant polyphenols on radiation-induced chromatid breaks in cultured human cells. Anticancer Research 1998; 18: 3263-3266.
139. Srinivasan M, Rajendra Prasad N, Menon VP. Protective effect of curcumin on γ-radiation induced DNA damage and lipid peroxidation in cultured human lymphocytes. Mutation Research-Genetic Toxicology and Environmental Mutagenesis 2006; 611: 96-103.
140. Oguro T, Yoshida T. Effect of ultraviolet A on ornithine decarboxylase and metallothionein gene expression in mouse skin. Photodermatology Photoimmunology and Photomedicine 2001; 17: 71-78.
141. Jagetia GC, Rajanikant GK. Role of curcumin, a naturally occurring phenolic compound of turmeric in accelerating the repair of excision wound, in mice whole-body exposed to various doses of γ-radiation. Journal of Surgical Research 2004; 120: 127-138.
142. Okunieff P, Xu J, Hu D, et al. Curcumin protects against radiationinduced acute and chronic cutaneous toxicity in mice and decreases mRNA expression of inflammatory and fibrogenic cytokines. International Journal of Radiation Oncology Biology Physics 2006; 65: 890-898.
143. Shaikh J, Ankola DD, Beniwal V, Singh D, Kumar MNVR. Nanoparticle encapsulation improves oral bioavailability of curcumin by at least 9-fold when compared to curcumin administered with piperine as absorption enhancer. European Journal of Pharmaceutical Sciences 2009; 37: 223-230.
144. Anindita Mukerjee JKV. Formulation, Characterization and Evaluation of Curcumin-loaded PLGA Nanospheres for Cancer Therapy. Anticancer Research 2009.
145. Anitha A, Deepagan VG, Rani VVD, et al. Preparation, characterization, in vitro drug release and biological studies of curcumin loaded dextran sulphate-chitosan nanoparticles. Carbohydrate Polymers 2011; 84: 1158-1164.
146. Rejinold NS, Muthunarayanan M, Divyarani VV, et al. Curcuminloaded biocompatible thermoresponsive polymeric nanoparticles for cancer drug delivery. J Colloid Interface Sci 2011; 360: 39-51.
147. Duan J, Zhang Y, Han S, et al. Synthesis and in vitro/in vivo anticancer evaluation of curcumin-loaded chitosan/poly(butyl cyanoacrylate) nanoparticles. Int J Pharm 2010; 400: 211-20.
148. Mazzarino L, Travelet C, Ortega-Murillo S, et al. Elaboration of chitosan-coated nanoparticles loaded with curcumin for mucoadhesive applications. J Colloid Interface Sci 2012; 370: 58-66.
149. Suwannateep N, Banlunara W, Wanichwecharungruang SP, et al. Mucoadhesive curcumin nanospheres: biological activity, adhesion to stomach mucosa and release of curcumin into the circulation. J Control Release 2011; 151: 176-82.
150. Mohanty C, Sahoo SK. The in vitro stability and in vivo pharmacokinetics of curcumin prepared as an aqueous nanoparticulate formulation. Biomaterials 2010; 31: 6597-6611.
151. Kim TH, Jiang HH, Youn YS, et al. Preparation and characterization of water-soluble albumin-bound curcumin nanoparticles with improved antitumor activity. Int J Pharm 2011; 403: 285-291.
152. Mulik RS, Monkkonen J, Juvonen RO, Mahadik KR, Paradkar AR. Transferrin mediated solid lipid nanoparticles containing curcumin: enhanced in vitro anticancer activity by induction of apoptosis. Int J Pharm 2010; 398: 190-203.
153. Kakkar V, Singh S, Singla D, Kaur IP. Exploring solid lipid nanoparticles to enhance the oral bioavailability of curcumin. Molecular Nutrition and Food Research 2011; 55: 495-503.
154. Mohanty C, Acharya S, Mohanty AK, Dilnawaz F, Sahoo SK. Curcumin-encapsulated MePEG/PCL diblock copolymeric micelles: A novel controlled delivery vehicle for cancer therapy. Nanomedicine 2010; 5: 433-449.
155. Raveendran R, Bhuvaneshwar GS, Sharma CP. In vitro cytotoxicity and cellular uptake of curcumin-loaded Pluronic/ Polycaprolactone micelles in colorectal adenocarcinoma cells. Journal of Biomaterials Applications 2012.
156. Song L, Shen Y, Hou J, et al. Polymeric micelles for parenteral delivery of curcumin: Preparation, characterization and in vitro evaluation. Colloids and Surfaces A: Physicochemical and Engineering Aspects 2011; 390: 25-32.
157. Song Z, Feng R, Sun M, et al. Curcumin-loaded PLGA-PEGPLGA triblock copolymeric micelles: Preparation, pharmacokinetics and distribution in vivo. J Colloid Interface Sci 2011; 354: 116-23.
158. Ding-Wei H, Tsang-Hao L, Chu IM. Encapsulation of curcumin by methoxy poly(ethylene glycol-b-aromatic anhydride) micelles. Journal of Applied Polymer Science 2011; 122.
159. Sahu A, Bora U, Kasoju N, Goswami P. Synthesis of novel biodegradable and self-assembling methoxy poly(ethylene glycol)-palmitate nanocarrier for curcumin delivery to cancer cells. Acta Biomater 2008; 4: 1752-1761.
160. Orr WS, Denbo JW, Saab KR, et al. Liposome-encapsulated curcumin suppresses neuroblastoma growth through nuclear factorkappa B inhibition. Surgery 2012.
161. Wang D, Veena MS, Stevenson K, et al. Liposome-encapsulated curcumin suppresses growth of head and neck squamous cell carcinoma in vitro and in xenografts through the inhibition of nuclear factor kappaB by an AKT-independent pathway. Clin Cancer Res 2008; 14: 6228-36.
162. Li L, Braiteh FS, Kurzrock R. Liposome-encapsulated curcumin-In vitro and in vivo effects on proliferation, apoptosis, signaling, and angiogenesis. Cancer 2005; 104: 1322-1331.
163. Thangapazham RL, Puri A, Tele S, Blumenthal R, Maheshwari RK. Evaluation of a nanotechnology-based carrier for delivery of curcumin in prostate cancer cells. International Journal of Oncology 2008; 32: 1119-1123.
164. Anuchapreeda S, Fukumori Y, Okonogi S, Ichikawa H. Preparation of Lipid Nanoemulsions Incorporating Curcumin for Cancer Therapy. Journal of Nanotechnology 2012; 2012: 1-11.
165. Ganta S, Amiji M. Coadministration of Paclitaxel and Curcumin in Nanoemulsion Formulations To Overcome Multidrug Resistance in Tumor Cells. Molecular Pharmaceutics 2009; 6: 928-939.
166. Yadav VR, Prasad S, Kannappan R, et al. Cyclodextrin-complexed curcumin exhibits anti-inflammatory and antiproliferative activities superior to those of curcumin through higher cellular uptake. Biochem Pharmacol 2010; 80: 1021-32.
167. Yallapu MM, Jaggi M, Chauhan SC. β-Cyclodextrin-curcumin self-assembly enhances curcumin delivery in prostate cancer cells. Colloids Surf B Biointerfaces 2010; 79: 113-25.
168. Ghosh M, Singh ATK, Xu W, et al. Curcumin nanodisks: formulation and characterization. Nanomedicine: Nanotechnology, Biology and Medicine 2011; 7: 162-167.
169. Singh ATK, Ghosh M, Forte TM, Ryan RO, Gordon LI. Curcumin nanodisk-induced apoptosis in mantle cell lymphoma. Leukemia & Lymphoma 2011; 52: 1537-1543.
170. Guo G, Fu S, Zhou L, et al. Preparation of curcumin loaded poly(epsilon-caprolactone)-poly(ethylene glycol)-poly(epsiloncaprolactone) nanofibers and their in vitro antitumor activity against Glioma 9L cells. Nanoscale 2011; 3: 3825-32.
171. Merrell JG, McLaughlin SW, Tie L, et al. Curcumin-loaded poly(ε-caprolactone) nanofibres: Diabetic wound dressing with antioxidant and anti-inflammatory properties. Clinical and Experimental Pharmacology and Physiology 2009; 36: 1149-1156.
172. Manju S, Sreenivasan K. Conjugation of curcumin onto hyaluronic acid enhances its aqueous solubility and stability. J Colloid Interface Sci 2011.
173. Li J, Wang Y, Yang C, et al. Polyethylene glycosylated curcumin conjugate inhibits pancreatic cancer cell growth through inactivation of Jab1. Mol Pharmacol 2009; 76: 81-90.
174. Manju S, Sreenivasan K. Synthesis and Characterization of a Cytotoxic Cationic Polyvinylpyrrolidone-Curcumin Conjugate. Journal of Pharmaceutical Sciences 2011; 100: 504-511.
175. Tang H, Murphy CJ, Zhang B, et al. Amphiphilic curcumin conjugate-forming nanoparticles as anticancer prodrug and drug carriers: in vitro and in vivo effects. Nanomedicine 2010; 5: 855-865.
176. Yallapu MM, Dobberpuhl MR, Maher DM, Jaggi M, Chauhan SC. Design of curcumin loaded cellulose nanoparticles for prostate cancer. Current Drug Metabolism 2012; 13: 120-128.
177. Ghosh D, Choudhury ST, Ghosh S, et al. Nanocapsulated curcumin: Oral chemopreventive formulation against diethylnitrosamine induced hepatocellular carcinoma in rat. Chemico-Biological Interactions 2012; 195: 206-214.
178. Yallapu MM, Gupta BK, Jaggi M, Chauhan SC. Fabrication of curcumin encapsulated PLGA nanoparticles for improved therapeutic effects in metastatic cancer cells. J Colloid Interface Sci 2010; 351: 19-29.
179. Anand P, Nair HB, Sung B, et al. Design of curcumin-loaded PLGA nanoparticles formulation with enhanced cellular uptake, and increased bioactivity in vitro and superior bioavailability in vivo. Biochem Pharmacol 2010; 79: 330-8.
180. Grabovac V, Bernkop-Schnurch A. Development and in vitro evaluation of surface modified poly(lactide-co-glycolide) nanoparticles with chitosan-4-thiobutylamidine. Drug Development and Industrial Pharmacy 2007; 33: 767-774.
181. Nair KL, Thulasidasan AK, Deepa G, Anto RJ, Kumar GS. Purely aqueous PLGA nanoparticulate formulations of curcumin exhibit enhanced anticancer activity with dependence on the combination of the carrier. Int J Pharm 2012; 425: 44-52.
182. Mulik R, Mahadik K, Paradkar A. Development of curcuminoids loaded poly(butyl) cyanoacrylate nanoparticles: Physicochemical characterization and stability study. European Journal of Pharmaceutical Sciences 2009; 37: 395-404.
183. Duan J, Mansour HM, Zhang Y, et al. Reversion of multidrug resistance by co-encapsulation of doxorubicin and curcumin in chitosan/poly(butyl cyanoacrylate) nanoparticles. Int J Pharm 2012; 426: 193-201.
184. Akhtar F, Rizvi MM, Kar SK. Oral delivery of curcumin bound to chitosan nanoparticles cured Plasmodium yoelii infected mice. Biotechnol Adv 2012; 30: 310-20.
185. Das RK, Kasoju N, Bora U. Encapsulation of curcumin in alginatechitosan-pluronic composite nanoparticles for delivery to cancer cells. Nanomedicine 2010; 6: 153-60.
186. Konatham S, Reddy B, Aukunuru J. Enhanced liver delivery and sustained release of curcumin with drug loaded nanoparticles after intravenous administration in rats. Asian Journal of Pharmaceutical Research and Health Care 2011; 3: 99-108.
187. Sanoj Rejinold N, Muthunarayanan M, Chennazhi KP, Nair SV, Jayakumar R. Curcumin loaded fibrinogen nanoparticles for cancer drug delivery. Journal of Biomedical Nanotechnology 2011; 7: 521-534.
188. Sun D, Zhuang X, Xiang X, et al. A novel nanoparticle drug delivery system: The anti-inflammatory activity of curcumin is enhanced when encapsulated in exosomes. Molecular Therapy 2010; 18: 1606-1614.
189. Manju S, Sreenivasan K. Gold nanoparticles generated and stabilized by water soluble curcumin-polymer conjugate: Blood compatibility evaluation and targeted drug delivery onto cancer cells. J Colloid Interface Sci 2012; 368: 144-151.
190. Tran LD, Hoang NMT, Mai TT, et al. Nanosized magnetofluorescent Fe 3O 4-curcumin conjugate for multimodal monitoring and drug targeting. Colloids and Surfaces A: Physicochemical and Engineering Aspects 2010; 371: 104-112.
191. Shao J, Zheng D, Jiang Z, et al. Curcumin delivery by methoxy polyethylene glycol-poly(caprolactone) nanoparticles inhibits the growth of C6 glioma cells. Acta Biochim Biophys Sin (Shanghai) 2011; 43: 267-274.
192. Tiyaboonchai W, Tungpradit W, Plianbangchang P. Formulation and characterization of curcuminoids loaded solid lipid nanoparticles. Int J Pharm 2007; 337: 299-306.
193. Li R, Qiao X, Li Q, et al. Metabolic and pharmacokinetic studies of curcumin, demethoxycurcumin and bisdemethoxycurcumin in mice tumor after intragastric administration of nanoparticle formulations by liquid chromatography coupled with tandem mass spectrometry. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences 2011; 879: 2751-2758.
194. Sou K, Inenaga S, Takeoka S, Tsuchida E. Loading of curcumin into macrophages using lipid-based nanoparticles. Int J Pharm 2008; 352: 287-293.
195. Chirio D, Gallarate M, Peira E, et al. Formulation of curcuminloaded solid lipid nanoparticles produced by fatty acids coacervation technique. J Microencapsul 2011; 28: 537-48.
196. Suresh D, Srinivasan K. Studies on the in vitro absorption of spice principles-Curcumin, capsaicin and piperine in rat intestines. Food and Chemical Toxicology 2007; 45: 1437-1442.
197. Ma Z, Shayeganpour A, Brocks DR, Lavasanifar A, Samuel J. High-performance liquid chromatography analysis of curcumin in rat plasma: Application to pharmacokinetics of polymeric micellar formulation of curcumin. Biomedical Chromatography 2007; 21: 546-552.
198. Leung MHM, Colangelo H, Kee TW. Encapsulation of curcumin in cationic micelles suppresses alkaline hydrolysis. Langmuir 2008; 24: 5672-5675.
199. Ma Z, Haddadi A, Molavi O, et al. Micelles of poly(ethylene oxide)-b-poly(ε-caprolactone) as vehicles for the solubilization, stabilization, and controlled delivery of curcumin. Journal of Biomedical Materials Research-Part A 2008; 86: 300-310.
200. Letchford K, Liggins R, Burt H. Solubilization of hydrophobic drugs by methoxy poly(ethylene glycol)-block-polycaprolactone diblock copolymer micelles: Theoretical and experimental data and correlations. J Pharm Sci 2008; 97: 1179-1190.
201. Gou M, Men K, Shi H, et al. Curcumin-loaded biodegradable polymeric micelles for colon cancer therapy in vitro and in vivo. Nanoscale 2011; 3: 1558-1567.
202. Sahu A, Kasoju N, Bora U. Fluorescence study of the curcumincasein micelle complexation and its application as a drug nanocarrier to cancer cells. Biomacromolecules 2008; 9: 2905-2912.
203. Sahu A, Kasoju N, Goswami P, Bora U. Encapsulation of curcumin in Pluronic block copolymer micelles for drug delivery applications. J Biomater Appl 2011; 25: 619-39.
204. Hong DW, Liu TH, Chu IM. Encapsulation of curcumin by methoxy poly(ethylene glycol-b-aromatic anhydride) micelles. Journal of Applied Polymer Science 2011; 122: 898-907.
205. Gardikis K, Dimas K, Georgopoulos A, et al. β-lactam functionalized poly(isoprene-b-ethylene oxide) amphiphilic block copolymer micelles as a new nanocarrier system for curcumin. Current Nanoscience 2010; 6: 277-284.
206. Rajeshl. Thangapazham AP, Shrikant Tele, Robert Blumenthal and Radha K. Maheshwari. Evaluation of a nanotechnology-based carrier for delivery of curcumin in prostate cancer cells. International Journal of Oncology 2008.
207. Pandelidou M, Dimas K, Georgopoulos A, Hatziantoniou S, Demetzos C. Preparation and characterization of lyophilised EGG PC liposomes incorporating curcumin and evaluation of its activity against colorectal cancer cell lines. Journal of Nanoscience and Nanotechnology 2011; 11: 1259-1266.
208. Lin YL, Liu YK, Tsai NM, et al. A Lipo-PEG-PEI complex for encapsulating curcumin that enhances its antitumor effects on curcumin-sensitive and curcumin-resistance cells. Nanomedicine: Nanotechnology, Biology, and Medicine 2012; 8: 318-327.
209. Gosangari SL, Watkin KL. Effect of preparation techniques on the properties of curcumin liposomes: Characterization of size, release and cytotoxicity on a squamous oral carcinoma cell line. Pharmaceutical Development and Technology 2012; 17: 103-109.
210. Yin YM, Cui FD, Mu CF, et al. Docetaxel microemulsion for enhanced oral bioavailability: Preparation and in vitro and in vivo evaluation. Journal of Controlled Release 2009; 140: 86-94.
211. Wang X, Jiang Y, Wang Y-W, et al. Enhancing anti-inflammation activity of curcumin through O/W nanoemulsions. Food Chemistry 2008; 108: 419-424.
212. Setthacheewakul S, Mahattanadul S, Phadoongsombut N, Pichayakorn W, Wiwattanapatapee R. Development and evaluation of self-microemulsifying liquid and pellet formulations of curcumin, and absorption studies in rats. Eur J Pharm Biopharm 2010; 76: 475-85.
213. Wu X, Xu J, Huang X, Wen C. Self-microemulsifying drug delivery system improves curcumin dissolution and bioavailability. Drug Development and Industrial Pharmacy 2011; 37: 15-23.
214. Ahmed K, Li Y, McClements DJ, Xiao H. Nanoemulsion-and emulsion-based delivery systems for curcumin: Encapsulation and release properties. Food Chemistry 2012; 132: 799-807.
215. Chen MJ, Chu YY, Lai PH, Cheng YM, Hsu YC. Experimental results of colorectal cancer chemoprevention by curcuminoids loaded nano-carrier drug delivery system increased in vitro biocompatibility. Digest Journal of Nanomaterials and Biostructures 2011; 6: 1187-1197.
216. Salmaso S, Bersani S, Semenzato A, Caliceti P. New cyclodextrin bioconjugates for active tumour targeting. Journal of Drug Targeting 2007; 15: 379-390.
217. Yallapu MM, Jaggi M, Chauhan SC. Poly(beta-cyclodextrin)/ curcumin self-assembly: a novel approach to improve curcumin delivery and its therapeutic efficacy in prostate cancer cells. Macromol Biosci 2010; 10: 1141-51.
218. Kazemi F, Zaraghami N, Aval SF, Monfaredan A. β-Cyclodextrincurcumin complex inhibit telomerase gene expression in T47-D breast cancer cell line. African Journal of Biotechnology 2011; 10: 19481-19488.
219. Dandawate PR, Vyas A, Ahmad A, et al. Inclusion Complex of Novel Curcumin Analogue CDF and β-Cyclodextrin (1:2) and Its Enhanced In vivo Anticancer Activity Against Pancreatic Cancer. Pharmaceutical Research 2012: 1-12.
220. Dhule SS, Penfornis P, Frazier T, et al. Curcumin-loaded γcyclodextrin liposomal nanoparticles as delivery vehicles for osteosarcoma. Nanomedicine: Nanotechnology, Biology, and Medicine 2011.
221. Tadmor T, Polliack A. Mantle cell lymphoma: Curcumin nanodisks and possible new concepts on drug delivery for an incurable lymphoma. Leukemia and Lymphoma 2011; 52: 1418-1420.
222. Ryan RO. Nanodisks: Hydrophobic drug delivery vehicles. Expert Opinion on Drug Delivery 2008; 5: 343-351.
223. Kumbar SG, Nukavarapu SP, James R, Nair LS, Laurencin CT. Electrospun poly(lactic acid-co-glycolic acid) scaffolds for skin tissue engineering. Biomaterials 2008; 29: 4100-4107.
224. Safavy A, Raisch KP, Mantena S, et al. Design and Development of Water-Soluble Curcumin Conjugates as Potential Anticancer Agents. J Med Chem 2007; 50: 6284-6288.
225. Shi W, Dolai S, Rizk S, et al. Synthesis of monofunctional curcumin derivatives, clicked curcumin dimer, and a PAMAM dendrimer curcumin conjugate for therapeutic applications. Organic Letters 2007; 9: 5461-5464.
226. Simoni E, Bergamini C, Fato R, et al. Polyamine Conjugation of Curcumin Analogues toward the Discovery of Mitochondria-Directed Neuroprotective Agents. J Med Chem 2010.
227. Willian Hansel BR. Curcumin Conjugates for Treating and Preventing Cancers. In: patent US, ed.̂eds., US 2011/0263500 A1: USA 2011.
228. Tang H, Murphy CJ, Zhang B, et al. Curcumin polymers as anticancer conjugates. Biomaterials 2010; 31: 7139-7149.